Emergent BioSolutions has partnered with Axiom Real-Time Metrics, a provider of unified eClinical solutions and services. Emergent has selected Axion’s Fusion eClinical suite as its global eClinical suite.
 
"Axiom is passionate about giving sponsors solutions that harness the power of their data to drive clinical research," said Andrew Schachter, founder and chief executive officer, Axiom. "We deliver technology and services to innovative life sciences organizations to provide them with the information that they need—in real-time—so that they are empowered with the robust and timely insights which are required for compliance, effective trial conduct, and successful drug development. We are very pleased to build this relationship with Emergent and potentially be a long-term partner in meeting their evolving needs as they develop drugs that are critical to patient well-being and position them at the leading edge of infectious disease treatments."
 
Paul-André de Lame, vice president, clinical development, Emergent, said, "We are delighted to have found a fully integrated clinical suite that will allow us to scale up seamlessly while optimizing our processes to capitalize on the unmatched potential offered by Axiom’s Fusion platform."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.